June 21, 2018
1 min read
Save

Reduction of proteinuria in children with CKD identified as target for therapy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Research in the Journal of the American Society of Nephrology shows that among children with CKD, ramipril reduced protein excretion in urine.

Sophie van den Belt

“This study shows that proteinuria, which has been known as an important renal and cardiovascular risk marker in adults, is also highly important with children with CKD,” Sophie van den Belt, MD, PhD, from the University Medical Center Groningen in the Netherlands, told Healio Nephrology. “It should be acknowledged that also in children, the lowering of proteinuria seems to be an important target for therapy.”

van den Belt and colleagues used the Effect of Strict Blood Pressure Control and ACE Inhibition on the Progression of CRF in Pediatric Patients Trial to conduct their research.

van den Belt and colleagues found 280 children with CKD (stage 2 to stage 4) received a fixed dose of ramipril. Investigators assessed initial proteinuria reduction and randomized the children to either conventional or intensified blood pressure control groups.

The initial proteinuria lowering in the conventional blood pressure control group was 40.2% and was 46.7% in the intensified blood pressure control group. Due to the similarities, the groups were combined, and investigators found ramipril therapy showed a reduction of proteinuria by a mean of 43.5% in children with CKD.

Among children with CKD, ramipril reduced protein excretion in urine
Source: AdobeStock

“The early antiproteinuric effect of ACE inhibition is associated with long-term preservation of renal function in children with CKD,” the researchers wrote. “Proteinuria lowering should be considered an important target in the management of pediatric CKD.” – by Jake Scott

 

Reference:

www.asn-online.org

 

Disclosures: van den Belt reports no relevant financial disclosures. Please see the full study for all other authors’ relevant financial disclosures.